Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 299

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 299
---
 and up to an additional aggregate amount of $450, so that the 2020 CLAs of
the non-Participating Lenders shall bear interest at 8% per annum until maturity commencing as of July 1, 2024, and of the Participating
Lenders commencing as of March 31, 2025. In addition, pursuant the October 2024 Addendum, upon the earlier of March 31, 2025 or occurrence
of an IPO, the CLA 2020 principal and accrued interest will be automatically converted into 243,955 ordinary shares based on a pre money
valuation of $5,150. In addition, the Company will pay to the Participating Lender an amount of $340 as a risk premium, which will be
automatically converted in the same terms as above into 221,456 Ordinary Shares of the Company. As of November 20, 2024, the Company
received $337.5 out of the $450 proceeds.

Between October 2024 and November 2024,
the Company entered into the October 2024 bridge loan agreements (the “Bridge Loans”), pursuant to which the Company obtained
a bridge loan from the lenders thereto including certain related parties (the “Bridge Loan Lenders”). The Bridge Loans shall
bear interest at 8% per annum until maturity and the Company agreed to pay the lenders an additional risk premium equal to 30% of their
respective loan amount. In October 2024, the Company amended the Bridge Loans pursuant to which the Bridge Loans may be extended beyond
March 31, 2025 and until June 30, 2025, subject to the Registration Statement effectiveness not later than March 31, 2025 and the fulfillment
of additional cumulative conditions. Furthermore, upon the occurrence of a Qualifying IPO, the Bridge Loan lenders, shall be granted
warrants to purchase such number of Ordinary Shares equal to two times their respective loan amount in addition to the risk premium based
on a price per share equal to 75% of the lowest price per share of the Company’ Ordinary Shares during the first five trading days
following the consummation of such initial public offering. The chairman of our board of directors is a lender under one of the Bridge
Loans. As of November 20, 2024, the Company received $117.5 out of the $500 proceeds.

<div align='center'>F-45

909,090 Ordinary Shares